Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer

BACKGROUND: Direct KRAS(G12C) inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination with platinum-doublet chemotherapy (chemo-immunotherapy). O...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkrief, Arielle, Ricciuti, Biagio, Alessi, Joao V, Fei, Teng, Kalvin, Hannah L, Egger, Jacklynn V, Rizvi, Hira, Thummalapalli, Rohit, Lamberti, Giuseppe, Plodkowski, Andrew, Hellmann, Matthew D, Kris, Mark G, Arcila, Maria E, Baine, Marina K, Rudin, Charles M, Lito, Piro, Ladanyi, Marc, Schoenfeld, Adam J, Riely, Gregory J, Awad, Mark M, Arbour, Kathryn C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628591/
https://www.ncbi.nlm.nih.gov/pubmed/37589215
http://dx.doi.org/10.1093/oncolo/oyad197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628591/
https://www.ncbi.nlm.nih.gov/pubmed/37589215
http://dx.doi.org/10.1093/oncolo/oyad197

Ejemplares similares